Mycapssa Capsule, Delayed Release
NDC 69880-120
Product Information
Mycapssa (octreotide) is a NDA-approved product labeled by Amryt Pharmaceuticals Designated Activity Company. This medication is typically used as a somatostatin analog [epc]. It is supplied as a white capsule, delayed release for oral administration. This product entry covers the primary NDC 69880-120 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
OT20
Code Structure Chart
Product Details
What is NDC 69880-120?
What are the uses of this product?
What are Active Ingredients of this product?
- OCTREOTIDE 20 mg/1 - A potent, long-acting synthetic SOMATOSTATIN octapeptide analog that inhibits secretion of GROWTH HORMONE and is used to treat hormone-secreting tumors; DIABETES MELLITUS; HYPOTENSION, ORTHOSTATIC; HYPERINSULINISM; hypergastrinemia; and small bowel fistula.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- OCTREOTIDE (UNII: RWM8CCW8GP)
- OCTREOTIDE (UNII: RWM8CCW8GP) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- POVIDONE K12 (UNII: 333AG72FWJ)
- SODIUM CAPRYLATE (UNII: 9XTM81VK2B)
- MAGNESIUM CHLORIDE (UNII: 02F3473H9O)
- POLYSORBATE 80 (UNII: 6OZP39ZG8H)
- GLYCERYL MONOCAPRYLATE (UNII: TM2TZD4G4A)
- TRICAPRILIN (UNII: 6P92858988)
- GELATIN, UNSPECIFIED (UNII: 2G86QN327L)
- METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A (UNII: NX76LV5T8J)
- TITANIUM DIOXIDE (UNII: 15FIX9V2JP)
- TRIETHYL CITRATE (UNII: 8Z96QXD6UM)
- SILICON DIOXIDE (UNII: ETJ7Z6XBU4)
- SODIUM BICARBONATE (UNII: 8MDF5V39QO)
- TALC (UNII: 7SEV7J4R1U)
- SODIUM LAURYL SULFATE (UNII: 368GB5141J)
- SHELLAC (UNII: 46N107B71O)
- FERROSOFERRIC OXIDE (UNII: XM0M87F357)
- PROPYLENE GLYCOL (UNII: 6DC9Q167V3)
- AMMONIA (UNII: 5138Q19F1X)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 2380611 - octreotide 20 MG Delayed Release Oral Capsule
- RxCUI: 2380611 - octreotide (as octreotide acetate) 20 MG Delayed Release Oral Capsule
- RxCUI: 2380617 - Mycapssa 20 MG Delayed Release Oral Capsule
- RxCUI: 2380617 - octreotide 20 MG Delayed Release Oral Capsule [Mycapssa]
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.
Patient Education
Octreotide
Octreotide is used to treat acromegaly (condition in which the body produces too much growth hormone, causing enlargement of the hands, feet, and facial features; joint pain; and other symptoms) in people who have been treated successfully with octreotide injection (Sandostatin) or lanreotide injection (Somatuline). Octreotide is in a class of medications called octapeptides. It works by decreasing the amounts of certain natural substances produced by the body.
[Learn More]
* Please review the full disclaimer at the bottom of this page.